Community protocol
Third-partySelank 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 0.5 mg
- 03Syringe units
- 5 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 5
Selank
A Russian-developed heptapeptide anxiolytic, registered in Russia. Trials exist but are small, largely Russian-language, and not independently replicated.
Overview
Selank is the immune peptide tuftsin with a short stabilising tail added so it survives long enough to act. Its reported effect is anxiety reduction without sedation and without the dependence risk of benzodiazepines. The proposed mechanism runs partly through the enkephalin system — it appears to slow the breakdown of the body's own opioid-like peptides — and partly through effects on GABA and serotonin signalling.
Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic analogue of the immunomodulatory tetrapeptide tuftsin extended with a Pro-Gly-Pro stabilising fragment. Reported to inhibit enkephalin-degrading enzymes, increasing endogenous enkephalin tone, and to modulate GABA-A receptor subunit expression, serotonin turnover and BDNF expression in rodent hippocampus. Registered in the Russian Federation as an anxiolytic administered intranasally. Clinical evidence consists of small Russian trials in generalised anxiety disorder and adjustment disorders; independent international replication is absent.
Research areas
AnxietyEnkephalin metabolismCognitive performance
Community-specified data
Community dosage information
Community protocol
Third-partyNA Selank Nasal Spray
- 01Reconstitution solution
- Not specified
- 02Dose
- 0.4 mg
- 03Syringe units
- 3 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- Not specified
- 07Bottle size
- 20 mg
- 08Bottles needed
- Not specified
Source note: 3 sprays per dose. No reconstitution needed.
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 0.15% intranasal solution, 300 mcg daily in divided doses for 14 days in generalised anxiety disorder | Russian clinical protocol |
| Comparison against medazepam in anxiety-asthenic disorders | Zozulya et al., Bulletin of Experimental Biology and Medicine 2008 |
Trial status
Small Russian clinical trials in anxiety disorders. No Western registered programme and no independent replication.
Reported safety signals
- Reported as well tolerated in Russian studies, but those studies are small and not independently verified.
- Nasal irritation is the commonly reported local effect.
- Effects on the endogenous opioid system have not been characterised over long-term use.
- Material sold outside Russia is unregulated and its identity is unverified.
Common questions
Is Selank addictive like a benzodiazepine?
No dependence or withdrawal has been reported in the available studies, and it does not act directly on the benzodiazepine site. That said, the studies are small and short, so an absence of reported dependence is not the same as demonstrated safety over long use.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →